An Open-Label, Single-Arm, Multicenter Pharmacokinetic Study of Intramuscular Erwinaze® (Asparaginase Erwinia Chrysanthemi)/Erwinase® (Crisantaspase)



Status:Recruiting
Conditions:Blood Cancer, Lymphoma, Lymphoma
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - 40
Updated:4/13/2015
Start Date:May 2014
Contact:Bengt Bergstrom, MD, PhD
Email:bengt.bergstrom@jazzpharma.com
Phone:650 496 3777

Use our guide to learn which trials are right for you!

An Open-Label, Single-Arm, Multicenter Pharmacokinetic Study of Intramuscular Erwinaze® (Asparaginase Erwinia Chrysanthemi)/Erwinase® (Crisantaspase) Administered Following Hypersensitivity to E. Coli Asparaginase in Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

The purpose of this study is to evaluate the serum asparaginase activity in subjects ages
18 to <40 years with ALL or LBL who have developed a hypersensitivity to native E. coli
asparaginase or pegaspargase.


Inclusion Criteria:

1. Have a diagnosis of ALL or LBL

2. Be 18 to <40 years of age at the time of enrollment

3. Have a documented ≥ Grade 2 clinical hypersensitivity reaction to native E. coli
asparaginase (e.g., Elspar or Kidrolase) or pegaspargase (Oncaspar)

4. Have the following asparaginase doses remaining in their treatment plan:

- At least two (2) consecutive weeks of native E. coli asparaginase treatment OR

- At least one (1) dose of pegaspargase (Oncaspar)

5. Have a direct bilirubin ≤ Grade 2 (<3.0 mg/dL [52 µmol/L])

6. Have amylase and lipase within normal limits (per institutional standards)

7. Have a serum asparaginase activity below the detectable limit during screening prior
to the first dose of study drug (Erwinaze)

8. Consent to use a medically acceptable method of contraception throughout the entire
study period and for 4 weeks after the study is completed. Medically acceptable
methods of contraception that may be used by the subject and/or the partner include
abstinence, birth control pills or patches, diaphragm and spermicide, condom and
vaginal spermicide, surgical sterilization, postmenopausal, vasectomy (>6 months
prior to baseline), and progestin implant or injection.

9. Have signed informed consent

Exclusion Criteria:

1. Prior history of ≥ Grade 3 pancreatitis

2. Prior history of a major thrombotic event as assessed by the investigator, or any
subject with a history of asparaginase-associated serious hemorrhagic or thrombotic
event requiring prolonged anticoagulation therapy with agents such as heparin

3. Prior treatment with Erwinaze

4. Pregnant or lactating female subjects or female subjects of childbearing potential
not willing to use an adequate method of birth control (listed above) for the
duration of the study

5. Subjects with a history of human immunodeficiency virus (HIV) or hepatitis.

6. Any other condition that would cause a risk (in the investigator's judgment) to
subjects if they participate in the trial
We found this trial at
6
sites
5801 South Ellis Avenue
Chicago, Illinois 60637
 773.702.1234
University of Chicago One of the world's premier academic and research institutions, the University of...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
666 Elm Street
Buffalo, New York 14263
(716) 845-2300
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
New Brunswick, New Jersey 08903
?
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Orange, California 92868
?
mi
from
Orange, CA
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19104
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
8th Ave & C St
Salt Lake City, Utah 84143
(801) 408-1100
LDS Hospital LDS Hospital provides clinical excellence to our community in a wide range of...
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials